GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TLSI · Mar 31, 2026

TriSalus Life Sciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-26-034100General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.58% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-72.82% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-2.92% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

42.45% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

86.18% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-94.52% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

36.14% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

27.78% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Dec 31, 20240/8 normalizedAmended as filed Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20260/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 2.03%
Current: 1.58%
Delta: -0.45%

Cash Generation Decreased

Previous: -39.89%
Current: -72.82%
Delta: -32.92%

Growth Decreased

Previous: 53.41%
Current: -2.92%
Delta: -56.34%

Inventory Pressure Increased

Previous: 6.81%
Current: 42.45%
Delta: 35.64%

Margin Increased

Previous: 84.57%
Current: 86.18%
Delta: 1.60%

Profitability Decreased

Previous: -59.68%
Current: -94.52%
Delta: -34.84%

R And D Intensity Increased

Previous: 33.14%
Current: 36.14%
Delta: 2.99%

Sbc Intensity Increased

Previous: 20.22%
Current: 27.78%
Delta: 7.56%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · TriSalus Life Sciences, Inc. →Transitioned To · TLSI PROFITABILITY_DECREASED →Transitioned To · TLSI R_AND_D_INTENSITY_INCREASED →Transitioned To · TLSI SBC_INTENSITY_INCREASED →Transitioned To · TLSI Fundamental State →Transitioned To · TLSI CAPEX_INTENSITY_DECREASED →Transitioned To · TLSI CASH_GENERATION_DECREASED →Transitioned To · TLSI GROWTH_DECREASED →Transitioned To · TLSI INVENTORY_PRESSURE_INCREASED →Transitioned To · TLSI MARGIN_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.